Prevalence of heterozygous familial hypercholesterolaemia and its impact on long-term prognosis in patients with very early ST-segment elevation myocardial infarction in the era of statins

Abstract Background and aims Familial hypercholesterolaemia (FH) is an important cause of early onset coronary artery disease. We assessed the prevalence of clinical heterozygous FH (HeFH) among patients with very early ST-segment elevation myocardial infarction (STEMI), its management and its impac...

Full description

Saved in:
Bibliographic Details
Published in:Atherosclerosis 2016-06, Vol.249, p.17-21
Main Authors: Rallidis, Loukianos S, Triantafyllis, Andreas S, Tsirebolos, Georgios, Katsaras, Dimitrios, Rallidi, Maria, Moutsatsou, Paraskevi, Lekakis, Jonh
Format: Article
Language:English
Subjects:
Adult
Algorithms
Cardiovascular
Cholesterol, LDL - blood
Familial hypercholesterolaemia
Female
Follow-Up Studies
Heterozygote
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use
Hyperlipoproteinemia Type II - diagnosis
Hyperlipoproteinemia Type II - drug therapy
Hyperlipoproteinemia Type II - genetics
Male
Premature myocardial infarction
Prevalence
Prognosis
Prospective Studies
Risk Factors
ST Elevation Myocardial Infarction - diagnosis
ST Elevation Myocardial Infarction - drug therapy
ST Elevation Myocardial Infarction - genetics
Statins
Time Factors
Treatment Outcome
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Background and aims Familial hypercholesterolaemia (FH) is an important cause of early onset coronary artery disease. We assessed the prevalence of clinical heterozygous FH (HeFH) among patients with very early ST-segment elevation myocardial infarction (STEMI), its management and its impact on long-term prognosis in the era of widespread utilization of statins. Methods We recruited prospectively 320 consecutive patients who had survived their first STEMI ≤35 years of age. Using the Dutch Lipid Clinic Network algorithm patients having HeFH (possible, probable or definite) were identified. Results Sixty-five patients (20.3%) had definite/probable HeFH and 163 patients (50.9%) had possible FH. Two years after discharge among 51 patients with definite/probable HeFH and available lipid levels, 43 (84.3%) were taking statins of whom 10 (23.3%) were on high-intensity statin therapy but only 1 (2.3%) of the statin-treated patients had LDL cholesterol levels
ISSN:0021-9150
1879-1484
DOI:10.1016/j.atherosclerosis.2016.03.023